AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04498689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Patients secondly receive nab-paclitaxel 100 mg/m2 (iv, at least 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the disease recurrence, unacceptable toxicity, death or begin a novel therapeutic.
Study NCT04498689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Injection
Description: At last, patients receive gemcitabine 1000 mg/m2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the disease recurrence, unacceptable toxicity, death or begin a novel therapeutic.
Study NCT02562638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-fasting
Description: Clear fluids up to 1hour pre-procedure and fasting for solids for up to 4 hours
Study NCT04195620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High self-disclosure
Description: The high self-disclosure condition involves individuals asking and answering a series of questions that are more personal in nature and involve sharing or receiving information that is likely to be emotionally laden and information that is not readily shared in typical conversations. An example of a question from this condition includes If you were to die today without the chance to speak with anyone, what would you most regret not having said to someone? Why haven't you said it yet?
Study NCT04195620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low self-disclosure
Description: The low self-disclosure condition involves individuals asking and answering a series of questions that are not personal in nature and involve sharing or receiving information that is shared in very casual conversations. An example of a question from this condition includes What did you do to celebrate Halloween last year?
Study NCT04310709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib/Nivolumab
Description: Combination of regorafenib and nivolumab
Study NCT01457586 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood transfusion
Description: Blood transfusion in perioperative period.
Study NCT01457586 — intervention group
Intervention type: BIOLOGICAL
Group type: NO_INTERVENTION
Intervention: No blood transfusion
Description: No transfusion in the perioperative period.
Study NCT04212208 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IV cannulation
Description: IV cannulation in the preoperative period
Study NCT04212208 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IV cannulation
Description: IV cannulation in the preoperative period
Study NCT04070690 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Concentration of dialysate bicarbonate
Description: Adjust the dialysate bicarbonate concentration
Study NCT03809468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phone call follow up
Description: instead of a clinic visit, patients will be randomized to a phone call
Study NCT01772745 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SILS cholecystectomy
Description: Single incision laparoscopic cholecystectomy will be performed
Study NCT01772745 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TPCL cholecystectomy
Description: Three port laparoscopic cholecystectomy will br performed
Study NCT03854370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baby shampoo
Description: baby shampoo will be used to prepare the surgical site prior to incision
Study NCT03854370 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Betadine
Description: Betadine (Povidone- iodine) will be used to prepare the surgical site prior to incision
Study NCT03854370 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peridex
Description: Peridex (Chlorhexidine) will be used to prepare the surgical site prior to incision
Study NCT03854370 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TechniCare
Description: TechniCare (chloroxynel) will be used to prepare the surgical site prior to incision
Study NCT00786331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 i.v. over approximately 10 minutes on day 1 of a 21 days cycle
Study NCT00786331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed plus carboplatin
Description: Pemetrexed 500 mg/m2 i.v. over approximately 10 minutes on day 1 and Carboplatin AUC 5 i.v. over approximately 30 minutes on day 1 (beginning approximately 30 minutes after the end of the pemetrexed infusion) of a 21 days cycle
Study NCT01500187 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vanish Varnish
Description: 5% sodium fluoride varnish with tricalcium phosphate
Study NCT01500187 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pediagel
Description: 1.23% Acidulated Phosphate Fluoride Gel
Study NCT00648622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol Tablets 12.5 mg
Description: 12.5mg, single dose fed
Study NCT00648622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coreg® Tablets 12.5 mg
Description: 12.5mg, single dose fed
Study NCT03138252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Study NCT00682370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: intravenous infusion, single dose
Study NCT00682370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: heme arginate
Description: intravenous infusion, single dose~0.3 mg/kg heme arginate
Study NCT00682370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: heme arginate
Description: intravenous infusion, single dose~1 mg/kg heme arginate
Study NCT00682370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: heme arginate
Description: intravenous infusion, single dose~3 mg/kg heme arginate
Study NCT03122743 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of serum samples
Study NCT03122743 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03122743 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02029989 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glucose and lipids
Description: Point-of-care (POCT) screening for diabetes and dyslipidemia.~Glucose and Lipids
Study NCT02029989 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glucose and lipids
Description: Point-of-care (POCT) screening for diabetes and dyslipidemia.~Glucose and Lipids
Study NCT02029989 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glycosylated Hemoglobin A1c
Description: Point-of-care (POCT) screening for diabetes~Glycosylated Hemoglobin A1c
Study NCT02029989 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glycosylated Hemoglobin A1c
Description: Point-of-care (POCT) screening for diabetes~Glycosylated Hemoglobin A1c
Study NCT02029989 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Pressure and Heart Rate
Description: Point-of-care (POCT) screening for hypertension~Blood Pressure and Heart Rate
Study NCT02029989 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Pressure and Heart Rate
Description: Point-of-care (POCT) screening for hypertension~Blood Pressure and Heart Rate
Study NCT02029989 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Body mass index
Description: Height and weight measurement used to calculate BMI = Mass(kg)/(height (m))squared
Study NCT02029989 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Body mass index
Description: Height and weight measurement used to calculate BMI = Mass(kg)/(height (m))squared
Study NCT02029989 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Waist and Hip circumference
Description: Measurement for Central Obesity~Waist and Hip circumference
Study NCT02029989 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Waist and Hip circumference
Description: Measurement for Central Obesity~Waist and Hip circumference
Study NCT02029989 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Medication Management
Description: Defined at http://www.pcpcc.org/guide/patient-health-through-medication-management
Study NCT01187498 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral training
Description: Comprehensive behavioral training program using delayed voiding, urge suppression techniques, pelvic floor muscle training, and monitoring with bladder diaries. Treatment is implemented by a nurse practitioner in 4 clinic visits over 8 weeks.
Study NCT01187498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybutynin chloride, extended-release
Description: Individually titrated, extended-release oxybutynin chloride, initiated at 10 mg, fluid management handout, and monitoring with bladder diaries. Treatment is implemented by a nurse practitioner in 4 clinic visits over 8 weeks.
Study NCT00006251 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI
Study NCT00006251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT00006251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given PO
Study NCT00006251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO
Study NCT00965003 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: Standard of Care
Study NCT00006251 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic PBSC transplant
Study NCT00006251 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: donor lymphocytes
Description: Undergo DLI
Study NCT00006251 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo allogeneic PBSC transplant
Study NCT00006251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02150733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 360 mg twice daily in the extension phase.
Study NCT02150733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 120 mg twice daily in the extension phase
Study NCT02150733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 120 mg once daily in the extension phase
Study NCT02150733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 120 mg once every other day in the extension phase
Study NCT00254176 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral cysteine-HCl supplementation
Description: cysteine-HCl supplementation 121 mg per kg per day
Study NCT00254176 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - added premasol
Description: Premasol 121 mg per kg per day
Study NCT03053063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL
Description: Tablets administered orally once daily
Study NCT03053063 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match SEL 6 mg
Description: Tablets administered orally once daily
Study NCT03053063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match SEL 6 mg
Description: Tablets administered orally once daily
Study NCT03053063 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match SEL 18 mg
Description: Tablets administered orally once daily
Study NCT03053063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match SEL 18 mg
Description: Tablets administered orally once daily
Study NCT04271319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BEST™ HVPC microcurrent electrical stimulation PRO-SPORT Ultra® Device
Description: Participants will receive treatment with an active electrical stimulation device for 7 in-clinic treatments over 2 weeks.~Active Avazzia PRO-Sport Ultra® medical device, BEST™ HVPC microcurrent electrical stimulation, FDA cleared for pain relief
Study NCT04271319 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham PRO-SPORT Ultra® Device
Description: Participants will receive treatment with a sham electrical stimulation device for 7 in-clinic treatments over 2 weeks.~Sham PRO-SPORT Ultra® device will be used. The built in electrodes and the accessory port for connecting the lead wire to the electrode pads will be disconnected internal to the device. The device will power on with the same sounds and indications.
Study NCT03030989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Gluconate 2% Wipe
Study NCT03030989 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Wipe
Study NCT00569647 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Hypnosis
Description: Use of virtual reality headset to induce hypnotic state
Study NCT00569647 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: no use of device
Study NCT02130804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate (4 g/day)
Description: Given orally twice daily
Study NCT02130804 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (4 g/day)
Description: Given orally twice daily
Study NCT04830384 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fully Active
Description: 7 subjects will be dispensed active treatment devices with light and music fully functional
Study NCT04830384 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LLLT Only
Description: 7 subjects will be dispensed active treatment devices with only light functional
Study NCT04830384 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Music Only
Description: 7 subjects will be dispensed placebo comparator devices with only music functional
Study NCT04830384 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: 7 subjects will be dispensed placebo or sham devices with no light or music functional
Study NCT03706885 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sustiva Pill
Description: One pill (Sustiva 50 mg or Sustiva 200mg or Placebo) One pill per day for 20 weeks
Study NCT03706885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sustiva Pill
Description: One pill (Sustiva 50 mg or Sustiva 200mg or Placebo) One pill per day for 20 weeks
Study NCT01051544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FVIII Concentrates
Description: Patients will be centrally randomized to receive a von Willebrand factor-free FVIII concentrate (recombinant or plasma-derived, monoclonally-purified). The choice of product brand will be based on physician / patients preferences.
Study NCT01051544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FVIII/VWF concentrates
Description: Patients will be centrally randomized to receive a FVIII/VWF concentrate of 200 IU/Kg by one or two bolus injections daily.The choice of product brand will be based on physician / patients preferences.
Study NCT02490787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concizumab
Description: Administered subcutaneously (s.c., under the skin) at five different dose levels (ranging from 0.25 to 1.5 mg/kg)
Study NCT02490787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administered subcutaneously (s.c., under the skin)
Study NCT02490787 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered subcutaneously (s.c., under the skin)
Study NCT02004886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0893
Description: 10 mg and 100 mg tablets
Study NCT02004886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 500 mg metformin tablets
Study NCT02004886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets matching MK-0893
Study NCT02004886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matching MK-0893
Study NCT02004886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matching MK-0893
Study NCT02004886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets matching metformin
Study NCT02004886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matching metformin
Study NCT01899742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umeclidinium/Vilanterol 62.5/25 mcg
Description: Inhalation Powder
Study NCT01899742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium 18 mcg
Description: Inhalation Powder
Study NCT03705650 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Limited Echocardiogram
Description: STUDY SOFTWARE non-significant risk (NSR) Bay Labs EchoGPS software interfaced with the Terason uSmart 3200t FDA 510(k)-cleared, commercially available ultrasound EchoGPS software communicates with the ultrasound image formation engine of the 510(k)-cleared Terason uSmart 3200t through an application programming interface (API). EchoGPS will be used to provide visual guidance, feedback and interpretation assistance to users during image acquisition. For this study, CMAs will use EchoGPS to perform point-of-care echocardiogram examinations.
Study NCT01690728 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: The intervention program will continue for six month consisting of two weekly sessions of 40 min exercise supervised by physiotherapists. The supervised exercise program will take place at the training center Fitness.dk in Esbjerg and Kolding. It will be in cooperation with physiotherapists at the Therapy Department of Sydvestjysk Sygehus Esbjerg and the Therapy Department of Fredericia and Kolding Sygehus, Sygehus Lillebælt. The exercise program at the two centers will be equal. In addition the patients will be provided with free access to a fitness center. The patient will be encouraged to do at least 3.5 hours of moderate to vigorous physical activity per week.
Study NCT02354755 — intervention group
Intervention type: DEVICE
Intervention: Psychomotor vigilance test (PVT
Description: The Psychomotor Vigilance Task Monitor is a hand-held, self-contained system used for repetitive reaction time measurements. The device measures the speed with which subject responds to visual stimulus (by pressing a response button).
Study NCT03321513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravitreous aflibercept
Description: Intravitreous aflibercept injection is made by Regeneron Pharmaceuticals, Inc. and is approved by the FDA for the treatment of neovascular age-related macular degeneration, macular edema due to central retinal vein occlusion, macular edema due to branch retinal vein occlusion, diabetic macular edema, and diabetic retinopathy in eyes with diabetic macular edema.~Study eyes assigned to receive aflibercept will receive a dose of 2.0 mg in 0.05 cc. Aflibercept will be obtained commercially by the clinical site. The physical, chemical, and pharmaceutical properties and formulation of aflibercept are provided in the Package Insert.~Intravitreous Injection Technique The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used.~The injection will be performed using sterile technique
Study NCT03321513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravitreous aflibercept
Description: Intravitreous aflibercept injection is made by Regeneron Pharmaceuticals, Inc. and is approved by the FDA for the treatment of neovascular age-related macular degeneration, macular edema due to central retinal vein occlusion, macular edema due to branch retinal vein occlusion, diabetic macular edema, and diabetic retinopathy in eyes with diabetic macular edema.~Study eyes assigned to receive aflibercept will receive a dose of 2.0 mg in 0.05 cc. Aflibercept will be obtained commercially by the clinical site. The physical, chemical, and pharmaceutical properties and formulation of aflibercept are provided in the Package Insert.~Intravitreous Injection Technique The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used.~The injection will be performed using sterile technique